Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Williams

Showing results (101-110 of 102) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 102 results.
The New England Journal of Medicine|March 25, 2011
Pioglitazone for diabetes prevention in impaired glucose toleranceRalph A DeFronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Journal of Medicinal Chemistry|December 4, 2010
Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agentRupa S Shetty, Younghee Lee, Bin Liu, et al.
Pageof 11

Showing results (101-110 of 102) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 102 results.
The New England Journal of Medicine|March 25, 2011
Pioglitazone for diabetes prevention in impaired glucose toleranceRalph A DeFronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Journal of Medicinal Chemistry|December 4, 2010
Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agentRupa S Shetty, Younghee Lee, Bin Liu, et al.
Pageof 11